Khoja v. Orexigen Therapeutics, Inc.

CourtDistrict Court, S.D. California
DecidedApril 22, 2021
Docket3:15-cv-00540
StatusUnknown

This text of Khoja v. Orexigen Therapeutics, Inc. (Khoja v. Orexigen Therapeutics, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Khoja v. Orexigen Therapeutics, Inc., (S.D. Cal. 2021).

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 11 KARIM KHOJA, on behalf of himself and Case No.: 15-CV-540 JLS (KSC) all others similarly situated, 12 ORDER (1) VACATING HEARING; Plaintiff, 13 (2) GRANTING PRELIMINARY v. APPROVAL OF CLASS ACTION 14 SETTLEMENT; OREXIGEN THERAPEUTICS, INC., 15 (3) PROVISIONALLY CERTIFYING JOSEPH P. HAGAN, MICHAEL A. SETTLEMENT CLASS; 16 NARACHI, and PRESTON KLASSEN, (4) APPROVING NOTICE AND 17 Defendants. NOTICE PLAN; (5) APPOINTING CLASS COUNSEL AND CLASS 18 REPRESENTATIVE; 19 (6) APPOINTING SETTLEMENT ADMINISTRATOR; AND 20 (7) SETTING SCHEDULE FOR 21 FINAL APPROVAL PROCESS

22 (ECF No. 142) 23

24 Presently before the Court is Plaintiff Karim Khoja’s Unopposed Motion for 25 Preliminary Approval of Proposed Settlement (“Mot.,” ECF No. 142). The Court finds 26 this matter appropriate for decision without oral argument and vacates the hearing and takes 27 the matter under submission pursuant to Civil Local Rule 7.1(d)(1). Having reviewed the 28 terms of the proposed settlement agreement, Plaintiffs’ arguments, and the law, the Court 1 preliminarily concludes that the settlement falls within the range of reasonableness 2 warranting preliminary approval. Accordingly, the Court GRANTS the Motion.

3 GENERAL BACKGROUND 4 This litigation commenced on March 10, 2015, when Lisa Colley filed a complaint 5 alleging that Defendant Orexigen Therapeutics, Inc. (“Orexigen”) “made materially 6 misleading statements when it disclosed confidential 25% interim data from a large-scale 7 clinical trial (the “LIGHT” trial) of its weight loss drug, Contrave,” on March 3, 2015. 8 ECF No. 142-1 (“Mot. Mem.”) at 2–3. The news that Contrave may demonstrate 9 cardioprotective benefits caused Orexigen’s stock to close “31% higher than it did the day 10 before.” Id. at 3 (citation omitted). In a March 5, 2015 Forbes.com article, however, “a 11 senior FDA official condemned [Orexigen]’s disclosure, . . . causing the stock price to 12 plummet.” Id. (citations omitted). 13 Several related cases were filed premised on the same facts, see ECF No. 4, and on 14 June 22, 2015, Judge M. James Lorenz ordered the cases consolidated, appointed Karim 15 Khoja (“Lead Plaintiff” or “Plaintiff”) as lead plaintiff, and approved Kahn Swick & Foti, 16 LLP as lead counsel (“Class Counsel”), see generally ECF No. 43. On June 26, 2015, 17 Judge Lorenz recused himself from the case, which subsequently was reassigned to this 18 Court. See ECF No. 46. 19 On August 20, 2015, Lead Plaintiff filed a Consolidated Complaint, which added 20 allegations of further misleading statements by Orexigen on March 3 and May 8, 2015. 21 See generally ECF No. 55. Defendants Orexigen, Joseph P. Hagan, Michael A. Narachi, 22 and Preston Klassen (collectively, “Defendants”) moved to dismiss, see ECF No. 62, and 23 the Court granted Defendants’ motion, see ECF No. 76. Lead Plaintiff requested the Court 24 to enter judgment in Defendants’ favor so he could pursue an appeal, see ECF No. 77, and 25 Lead Plaintiff subsequently appealed the decision, see ECF No. 80. On March 12, 2018, 26 while the appeal was pending, Orexigen filed for Chapter 11 bankruptcy; the automatic 27 stay halted further proceedings against Orexigen, but not the remaining defendants 28 (collectively, the “Individual Defendants”). Mot. Mem. at 4 (citation omitted). 1 On August 13, 2018, the Ninth Circuit affirmed in part and reversed in part the 2 Court’s order dismissing Lead Plaintiff’s Consolidated Complaint. See ECF No. 93. The 3 Individual Defendants requested rehearing en banc, see ECF No. 85, which the Ninth 4 Circuit denied, see ECF No. 86. The Individual Defendants then filed a petition for writ of 5 certiorari with the Supreme Court, which ultimately was denied. See Mot. Mem. at 5 6 (citation omitted). 7 Following a mandate/status hearing, see ECF No. 92, the Court entered an order 8 setting a briefing schedule for the Individual Defendants’ renewed motion to dismiss, see 9 ECF No. 97. On September 23, 2019, the Court granted in part and denied in part the 10 Individual Defendants’ motion. See ECF No. 110. On October 17, 2019, Lead Plaintiff 11 filed the Consolidated Amended Complaint (“CAC”), see ECF No. 111, and Individual 12 Defendants again moved to dismiss, see ECF No. 114. 13 On March 13, 2020, the Parties participated in a daylong mediation facilitated by 14 Jed Melnick, Esq., of JAMS. See Mot. Mem. at 1, 5. After Orexigen’s wind-down 15 administrator, Province, Inc. (“Province”), filed a status report with the Ninth Circuit 16 informing the court that the bankruptcy stay had been lifted, on May 19, 2020, the Ninth 17 Circuit extended its prior order to Orexigen, and the mandate, noting the substitution of 18 Province for Orexigen, was spread to this Court on July 10, 2020. See id. at 5 n.2 (citations 19 omitted). 20 On November 2, 2020, the Court granted Defendants’ motion to dismiss. See ECF 21 No. 139. Thereafter, the Parties resumed settlement negotiations, and on December 7, 22 2020, they agreed to accept the mediator’s proposal to resolve the matter. Mot. Mem. at 6 23 (citation omitted). 24 SETTLEMENT TERMS 25 The Parties have submitted a comprehensive Stipulation of Settlement (“Proposed 26 Settlement” or “Stipulation”) with approximately thirty pages of substantive terms, see 27 / / / 28 / / / 1 generally Mot. Mem. Ex. 1 (“Proposed Settlement,” ECF No. 142-3), as well as a 2 comprehensive Notice of Pendency and Proposed Settlement of Class Action (“Proposed 3 Notice”), see generally Mot. Mem. Ex. A-1 (“Proposed Notice,” ECF No. 142-5); 4 Summary Notice, see generally Mot. Mem. Ex. A-2 (ECF No. 142-6); and Proof of Claim 5 and Release Form, see generally Mot. Mem. Ex. A-3 (“Proof,” ECF No. 142-7). 6 I. Proposed Settlement Class 7 The proposed Settlement Class includes “all Persons who purchased or otherwise 8 acquired Orexigen publicly traded securities between March 3, 2015 and May 12, 2015, 9 inclusive,” excluding “Defendants, all directors and officers of Orexigen (whether current 10 or former), each of their respective immediate family members, and entities in which any 11 such excluded person holds a controlling interest.” Proposed Settlement ¶ 1.26. 12 II. Proposed Monetary Relief 13 The Proposed Settlement provides for a $4,800,000 Settlement Amount. Proposed 14 Settlement ¶ 1.25. The Settlement Amount will be applied as follows: to pay the reasonable 15 costs and expenses of the Claims Administrator incurred in connection with providing 16 notice and administrating the settlement (not to exceed $250,000); to pay certain taxes and 17 tax expenses; to pay Class Counsel’s fees (not to exceed thirty-three percent of the 18 Settlement Amount); and to pay Class Counsel’s and Lead Plaintiff’s expenses (not to 19 exceed $185,000); with the balance (the “Net Settlement Fund”) to be distributed to 20 Authorized Claimants. See id. ¶ 6.2; Proposed Notice at 1. 21 Each Settlement Class Member who wishes to receive a portion of the Net 22 Settlement Fund must submit a Proof of Claim and Release Form by the date provided in 23 the Proposed Notice. See Proposed Settlement ¶ 6.3(a). Any Settlement Class Member 24 who fails to submit a timely Proof of Claim and Release Form will be barred from receiving 25 payment but otherwise bound by the terms of the Proposed Settlement. See id. ¶ 6.3(b). 26 27 28 1 Capitalized terms used in this Order shall have the same meanings as set forth in the Proposed Settlement, 1 Before the deduction of fees, costs, and expenses, Plaintiff’s damages expert estimates the 2 average recovery per share, if valid claims are submitted for all approximately 25 million 3 shares of Orexigen securities purchased during the Class Period, to be $0.19. Proposed 4 Notice ¶ 3. 5 Each Authorized Claimant will receive a proportionate share of the Net Settlement 6 Fund based on a recognized loss formula. See id. ¶¶ 49–71.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hansberry v. Lee
311 U.S. 32 (Supreme Court, 1940)
General Telephone Co. of Southwest v. Falcon
457 U.S. 147 (Supreme Court, 1982)
Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
Burrell v. Hampshire County
307 F.3d 1 (First Circuit, 2002)
Wal-Mart Stores, Inc. v. Dukes
131 S. Ct. 2541 (Supreme Court, 2011)
United States v. Harold M. Romanow
509 F.2d 26 (First Circuit, 1975)
Jon Michael Hunter v. F.P. Samples, Warden
15 F.3d 1011 (Eleventh Circuit, 1994)
Robin Zinser v. Accufix Research Institute, Inc.
253 F.3d 1180 (Ninth Circuit, 2001)
Rodriguez v. West Publishing Corp.
563 F.3d 948 (Ninth Circuit, 2009)
In Re Tableware Antitrust Litigation
484 F. Supp. 2d 1078 (N.D. California, 2007)
True v. American Honda Motor Co.
749 F. Supp. 2d 1052 (C.D. California, 2010)
In re Cooper Companies Inc. Securities Litigation
254 F.R.D. 628 (C.D. California, 2009)
Mccowen v. Trimac Transportation Services (Western), Inc.
311 F.R.D. 579 (N.D. California, 2015)
Schwartz v. Harp
108 F.R.D. 279 (C.D. California, 1985)

Cite This Page — Counsel Stack

Bluebook (online)
Khoja v. Orexigen Therapeutics, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/khoja-v-orexigen-therapeutics-inc-casd-2021.